Followers | 19 |
Posts | 1611 |
Boards Moderated | 0 |
Alias Born | 03/21/2017 |
Friday, December 07, 2018 6:05:00 PM
Endonovo Therapeutics Affects 1-for-100 Reverse Stock Split
Recapitalization Plan
Additionally, the Company announced that it expects to issue approximately 75 million additional post-split shares to various affiliates, professionals, vendors, note holders and others as part of a plan to recapitalize the Company's balance sheet.
As part of the recapitalization plan, the Company announced that it is offering certain note holders of the Company's current outstanding debt (the "Note Holders") the option to convert the principle amount of their notes and any accrued interest (the "Notes") into shares of the Company's common stock at a price of $0.50 per share (the "Conversion").
The Conversion will allow Endonovo to strengthen its balance sheet in order to attract additional capital to fund the Company's commercialization efforts, develop additional technologies in its portfolio of regenerative therapies and up-list the Company's common stock onto the NASDAQ Capital Market.
"We believe that Endonovo Therapeutics is significantly undervalued in the market based on our pipeline of bioelectronic and regenerative therapies," stated Alan Collier, Chairman and CEO of Endonovo Therapeutics. "This is the first step to meeting the initial listing requirements of the NASDAQ Capital Market, which may allow us to receive a higher valuation, better market support and facilitate the raising of additional capital to support the commercialization of our technologies."
They would probably recycle this PR given how shameless they are.
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/25/2023 11:04:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:16:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM